Zebrafish Models of Prader-Willi Syndrome: Fast Track to Pharmacotherapeutics

• Main Authors: Emma D. Spikol, Caroline E. Laverriere, Maya Robnett, Gabriela Carter, Erin Wolfe, Eric Glasgow
• Format: Article
• Language: English
• Published: MDPI AG 2016-03-01
• Series: Diseases
• Subjects: neuroendocrine; oxytocin; zebrafish
• Online Access: http://www.mdpi.com/2079-9721/4/1/13

Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder characterized by an insatiable appetite, leading to chronic overeating and obesity. Additional features include short stature, intellectual disability, behavioral problems and incomplete sexual development. Although significant progress has been made in understanding the genetic basis of PWS, the mechanisms underlying the pathogenesis of the disorder remain poorly understood. Treatment for PWS consists mainly of palliative therapies; curative therapies are sorely needed. Zebrafish, Danio rerio, represent a promising way forward for elucidating physiological problems such as obesity and identifying new pharmacotherapeutic options for PWS. Over the last decade, an increased appreciation for the highly conserved biology among vertebrates and the ability to perform high-throughput drug screening has seen an explosion in the use of zebrafish for disease modeling and drug discovery. Here, we review recent advances in developing zebrafish models of human disease. Aspects of zebrafish genetics and physiology that are relevant to PWS will be discussed, and the advantages and disadvantages of zebrafish models will be contrasted with current animal models for this syndrome. Finally, we will present a paradigm for drug screening in zebrafish that is potentially the fastest route for identifying and delivering curative pharmacotherapies to PWS patients.